Universal Display OLED Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross

Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross at other companies

Beam TherapeuticsBEAM

$30.08M-12.6%

IQVIAIQV

$1.68B+8.0%

Dianthus TherapeuticsDNTH

$8.64M+47.7%

Tango TherapeuticsTNGX

$12.93M-6.6%

Hayward HoldingsHAYW

$6.76M+12.9%

ChemoursCC

$26M-3.7%

Other financials

Income statement

See full

Revenue$142.2M-14.5%

Gross profit$106.1M-17.2%

Operating income$42.8M-38.6%

Net income$35.9M-44.3%

EPS (diluted)$0.76-43.7%

Balance sheet

See full

Cash & equivalents$159.4M—

Total debt$40.9M—

Total equity$1.7B+2.7%

Total assets$1.9B—

Cash flow

See full

Operating cash flow$108.9M+256%

CapEx$8.6M-34.1%

Free cash flow$100.3M+473%

Valuation

See full

Market cap$4B-34.8%

Profitability

See full

Gross margin75.7%-1.2pp

Operating margin35.4%-2.5pp

Net margin34.1%-1.3pp

FCF margin37.8%+12.6pp

Returns & leverage

See full

Return on equity12.7%-1.9pp

Debt / equity0×—

Current ratio9.5×—

Where this comes from

Reported directly by Universal Display in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross.

The official record: Universal Display’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Universal Display's research and development arrangement contract to perform for others costs incurred gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Universal Display's research and development arrangement contract to perform for others costs incurred gross?: Universal Display (OLED) reported research and development arrangement contract to perform for others costs incurred gross of $5.8M in Q1 2026.